Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.83+0.46 (+7.22%)
At close: 04:00PM EST
6.89 +0.06 (+0.88%)
After hours: 07:49PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Shooting Star

Shooting Star

Previous Close6.37
Open6.56
Bid6.79 x 1100
Ask6.90 x 1400
Day's Range6.53 - 7.02
52 Week Range4.02 - 43.12
Volume3,367,314
Avg. Volume3,418,013
Market Cap663.674M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-2.44
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FATE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fate Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    17 days agoArgus Research
View more
  • GlobeNewswire

    GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

    BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities. The full letter is published below: Dear GT Biopharma Shareholders, I am proud to say that we have made significant

  • Simply Wall St.

    Calculating The Fair Value Of Fate Therapeutics, Inc. (NASDAQ:FATE)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Fate Therapeutics...

  • Insider Monkey

    12 Cash-Rich Small Cap Stocks To Invest In

    In this article, we will take a look at the 12 cash-rich small cap stocks to invest in. To see more such companies, go directly to 5 Cash-Rich Small Cap Stocks To Invest In. In 2022, standard diversified portfolios suffered through their worst-performing year in a century. Despite the decline in markets this past year, […]

Advertisement
Advertisement